A BILL 
To amend title XVIII of the Social Security Act to provide 
a review process for adverse national coverage determina-
tions with respect to drug coverage under the Medicare 
program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Access to Innovative 
4
Treatments Act of 2022’’. 
5
16:17 Nov 30, 2022
H9358
2 
•HR 9358 IH
SEC. 2. PROVIDING A REVIEW PROCESS FOR ADVERSE NA-
1
TIONAL COVERAGE DETERMINATIONS WITH 
2
RESPECT TO DRUG COVERAGE UNDER THE 
3
MEDICARE PROGRAM. 
4
(a) IN GENERAL.—Section 1862(l) of the Social Se-
5
curity Act (42 U.S.C. 1395y(l)) is amended— 
6
(1) by redesignating paragraphs (5) and (6) as 
7
paragraphs (7) and (8), respectively; and 
8
(2) by inserting after paragraph (4) the fol-
9
lowing new paragraphs: 
10
‘‘(5) REVIEW OF NATIONAL COVERAGE DETER-
11
MINATIONS FOR DRUGS AND BIOLOGICALS.— 
12
‘‘(A) IN
GENERAL.—Subject to subpara-
13
graph (D), not later than 30 days after receiv-
14
ing a request for a review of a specified na-
15
tional coverage determination (as defined in 
16
subparagraph (E)), the Secretary shall initiate 
17
such a review in accordance with the provisions 
18
of this paragraph. 
19
‘‘(B) PUBLIC COMMENT PERIOD.—Begin-
20
ning on the date of the initiation of a review of 
21
a specified national coverage determination 
22
under subparagraph (A), the Secretary shall 
23
provide for a 30-day public comment period as 
24
to whether such determination should be af-
25
firmed, reversed, or otherwise modified. 
26
16:17 Nov 30, 2022
H9358
3 
•HR 9358 IH
‘‘(C) FINAL DECISION.—Not later than 30 
1
days after the conclusion of the 30-day period 
2
described in subparagraph (B) with respect to 
3
a specified national coverage determination, the 
4
Secretary shall— 
5
‘‘(i) make a final decision as to wheth-
6
er such determination should be affirmed, 
7
reversed, or otherwise modified; 
8
‘‘(ii) include in such final decision 
9
summaries of the public comments received 
10
and responses to such comments; 
11
‘‘(iii) make available to the public the 
12
clinical evidence and other data used in 
13
making such decision when such decision 
14
differs from the recommendations of the 
15
Medicare Coverage Advisory Committee; 
16
and 
17
‘‘(iv) in the case of a final decision 
18
under clause (i) to reverse or modify such 
19
determination, the Secretary shall assign a 
20
temporary or permanent code (whether ex-
21
isting or unclassified) and implement the 
22
coding change as applicable. 
23
‘‘(D) LIMITATION
ON
SUCCESSIVE
RE-
24
VIEWS.—Subparagraph (A) shall not apply with 
25
16:17 Nov 30, 2022
H9358
4 
•HR 9358 IH
respect to a request for a review of a specified 
1
national coverage determination if the Secretary 
2
has made a final decision with respect to a pre-
3
vious review of such determination under this 
4
paragraph during the 2-year period ending on 
5
the date of the receipt of such request. Nothing 
6
in the preceding sentence shall be construed to 
7
limit the authority of the Secretary to review or 
8
reconsider a national coverage determination if 
9
determined appropriate by the Secretary. 
10
‘‘(E) SPECIFIED NATIONAL COVERAGE DE-
11
TERMINATION
DEFINED.—In this paragraph, 
12
the term ‘specified national coverage determina-
13
tion’ means a national coverage determination 
14
made with respect to a drug or biological ap-
15
proved under section 505(c) of the Federal 
16
Food, Drug, and Cosmetic Act or licensed 
17
under section 351 of the Public Health Service 
18
Act under which coverage of such drug or bio-
19
logical under this title was denied or otherwise 
20
limited in a manner inconsistent with such ap-
21
proval or licensure. 
22
‘‘(6) PROHIBITION ON APPLICATION OF CER-
23
TAIN EXISTING NATIONAL COVERAGE DETERMINA-
24
TIONS
TO
NEWLY-APPROVED
DRUGS
AND 
25
16:17 Nov 30, 2022
H9358
5 
•HR 9358 IH
BIOLOGICALS.—The Secretary may not, with respect 
1
to a drug approved under section 505(c) of the Fed-
2
eral Food, Drug, and Cosmetic Act or a biological 
3
licensed under section 351 of the Public Health 
4
Service Act, apply a national coverage determination 
5
that was made prior to the date of such approval or 
6
licensure (as applicable) to the extent that such ap-
7
plication would result in a denial or other limit of 
8
coverage under this title for such drug or biological 
9
in a manner inconsistent with such approval or li-
10
censure.’’. 
11
(b) NONRELIANCE ON CERTAIN NCDS UNDER PART 
12
D.—Section 1860D–2(e)(3) of the Social Security Act (42 
13
U.S.C. 1395w–102(e)(3)) is amended by adding at the end 
14
the following new sentence: ‘‘In determining whether pay-
15
ment would not be made with respect to a covered part 
16
D drug if section 1862(a) applied to this part, a prescrip-
17
tion drug plan or MA–PD plan may not base such deter-
18
mination on a national coverage determination made with 
19
respect to such drug if such determination is a specified 
20
national coverage determination (as defined in section 
21
1862(l)(5)).’’. 
22
Æ 
16:17 Nov 30, 2022
H9358
